HC Wainwright Lowers Earnings Estimates for Ekso Bionics

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) – Equities research analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for Ekso Bionics in a note issued to investors on Tuesday, March 4th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.11) per share for the quarter, down from their previous estimate of ($0.06). HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Ekso Bionics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Ekso Bionics’ Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.25) EPS and FY2028 earnings at $0.27 EPS.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.07). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The company had revenue of $5.09 million for the quarter, compared to analyst estimates of $5.05 million.

Several other brokerages have also recently commented on EKSO. StockNews.com initiated coverage on Ekso Bionics in a research report on Monday. They set a “hold” rating for the company. Lake Street Capital cut their price objective on Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a research report on Tuesday.

Ekso Bionics Stock Performance

Shares of NASDAQ EKSO opened at $0.40 on Thursday. The stock has a 50 day moving average price of $0.61 and a 200 day moving average price of $0.82. Ekso Bionics has a 52 week low of $0.37 and a 52 week high of $1.64. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The stock has a market capitalization of $8.86 million, a PE ratio of -0.62 and a beta of 1.46.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.